Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800) February 26, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering February 11, 2020 • 4:01 PM EST
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD February 5, 2020 • 5:15 PM EST
Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences February 4, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference January 29, 2020 • 4:15 PM EST
Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL January 24, 2020 • 7:00 AM EST
Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference January 23, 2020 • 7:00 AM EST
Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study December 16, 2019 • 3:15 PM EST
